Search
Search Results
-
HOXA7 promotes the metastasis of KRAS mutant colorectal cancer by regulating myeloid-derived suppressor cells
BackgroundKRAS mutation accounts for 30–50% of human colorectal cancer (CRC) cases. Due to the scarcity of effective treatment options, KRAS mutant...
-
The value of haematological parameters and serum tumour markers for predicting KRAS mutations in 784 Chinese colorectal cancer patients: a retrospective analysis
BackgroundIdentifying the mutation status of KRAS is important for optimizing treatment in patients with colorectal cancer (CRC). The aim of this...
-
APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells
BackgroundAberrant WNT/β-catenin signaling drives carcinogenesis. Tankyrases poly(ADP-ribosyl)ate and destabilize AXINs, β-catenin repressors....
-
HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism
BackgroundHistone deacetylases (HDAC) contribute to oncogenic program, pointing to their inhibitors as a potential strategy against cancers. We,...
-
KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma
BackgroundWhile the correlation between PD-L1 expression and KRAS mutation has been previously reported in other solid tumors such as non-small cell...
-
Searching for treatments for non-G12C-KRAS mutant cancers
KRAS mutations drive a wide variety of cancers. Drugs targeting the protein product of KRAS G12C mutations are currently being evaluated show...
-
Source, co-occurrence, and prognostic value of PTEN mutations or loss in colorectal cancer
Somatic PTEN mutations are common and have driver function in some cancer types. However, in colorectal cancers (CRCs), somatic PTEN -inactivating...
-
Associations between nutritional factors and KRAS mutations in colorectal cancer: a systematic review
BackgroundBetween 30 and 50% of colon tumors have mutations in the Kirsten- ras ( KRAS ) gene, which have a large nutritional attributable risk....
-
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
BackgroundCholangiocarcinoma (CCA) is still a deadly tumour. Histological and molecular aspects of thioacetamide (TAA)-induced intrahepatic CCA...
-
Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomes
IntroductionAcute myeloid leukemia (AML) is a complex hematologic malignancy characterized by uncontrolled proliferation of myeloid precursor cells...
-
Leukotriene B4 receptor-2 contributes to KRAS-driven lung tumor formation by promoting interleukin-6-mediated inflammation
Although lung cancer is the leading cause of cancer-related deaths worldwide and KRAS is the most frequently mutated oncogene in lung cancer cases,...
-
Identification of cancer driver mutations in liquid-based cytology samples for the screening of endometrial diseases
BackgroundEndometrial cancer (EC) is one of the leading causes of cancer death among women and early detection is crucial for its successful...
-
Detection of low-frequency mutations in clinical samples by increasing mutation abundance via the excision of wild-type sequences
The efficiency of DNA-enrichment techniques is often insufficient to detect mutations that occur at low frequencies. Here we report a DNA-excision...
-
Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome
Functional perturbations of the cohesin complex with subsequent changes in chromatin structure and replication are reported in a multitude of cancers...
-
A PCR-Based Approach for Driver Mutation Analysis of EGFR, KRAS, and BRAF Genes in Lung Cancer Tissue Sections
Driver mutations in non-small cell lung cancer (NSCLC) have a relevant significance for clinical management. EGFR mutations are the most important...
-
Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD
BackgroundThe treatment for colon adenocarcinoma (COAD) faces challenges in terms of immunotherapy effectiveness due to multiple factors. Because of...
-
Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
BackgroundKRAS is the most frequently mutated oncogene in cancer, however efforts to develop targeted therapies have been largely unsuccessful....
-
Lack of shared neoantigens in prevalent mutations in cancer
Tumors are mostly characterized by genetic instability, as result of mutations in surveillance mechanisms, such as DNA damage checkpoint, DNA repair...
-
Somatic Mutations in the BRAF, KRAS, NRAS, EIF1AX, and TERT Genes: Diagnostic Value in Thyroid Neoplasms
The feasibility of using molecular genetic markers associated with thyroid neoplasms and more aggressive course of the disease is now actively...
-
Creation of an Isogenic H/N/KRAS-Less Mouse Embryonic Fibroblast Cell Line Panel Derived from a Size-Sorted Diploid Clone
Cell line panels have proven to be an invaluable tool for investigators researching a range of topics from drug mechanism or drug sensitivity studies...